SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biora Therapeutics, Inc. – ‘10-Q’ for 6/30/22

On:  Monday, 8/15/22, at 5:37pm ET   ·   For:  6/30/22   ·   Accession #:  950170-22-17429   ·   File #:  1-39334

Previous ‘10-Q’:  ‘10-Q’ on 5/10/22 for 3/31/22   ·   Next:  ‘10-Q’ on 11/14/22 for 9/30/22   ·   Latest:  ‘10-Q’ on 11/13/23 for 9/30/23   ·   2 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/15/22  Biora Therapeutics, Inc.          10-Q        6/30/22   74:10M                                    Donnelley … Solutions/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   3.29M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     27K 
10: R1          Document and Entity Information                     HTML     78K 
11: R2          Condensed Consolidated Balance Sheets (Unaudited)   HTML    119K 
12: R3          Condensed Consolidated Balance Sheets               HTML     35K 
                (Parenthetical) (Unaudited)                                      
13: R4          Condensed Consolidated Statements of Operations     HTML     86K 
                (Unaudited)                                                      
14: R5          Condensed Consolidated Statements of Stockholders'  HTML    100K 
                Deficit (Unaudited)                                              
15: R6          Condensed Consolidated Statements of Cash Flows     HTML    148K 
                (Unaudited)                                                      
16: R7          Organization and Description of Business            HTML     40K 
17: R8          Summary of Significant Accounting Policies          HTML     98K 
18: R9          Variable Interest Entities                          HTML     29K 
19: R10         Strategic Transformation                            HTML    144K 
20: R11         Revenues                                            HTML     97K 
21: R12         Balance Sheet Components                            HTML    167K 
22: R13         Fair Value Measurements                             HTML     89K 
23: R14         Convertible Notes                                   HTML     52K 
24: R15         Related Party Transactions                          HTML     30K 
25: R16         Commitments and Contingencies                       HTML    109K 
26: R17         Stockholders' Equity                                HTML     70K 
27: R18         Stock-Based Compensation                            HTML    167K 
28: R19         Income Taxes                                        HTML     33K 
29: R20         Net Loss Per Share                                  HTML     47K 
30: R21         Summary of Significant Accounting Policies          HTML    120K 
                (Policies)                                                       
31: R22         Summary of Significant Accounting Policies          HTML     63K 
                (Tables)                                                         
32: R23         Strategic Transformation (Tables)                   HTML    140K 
33: R24         Revenues (Tables)                                   HTML     78K 
34: R25         Balance Sheet Components (Tables)                   HTML    166K 
35: R26         Fair Value Measurements (Tables)                    HTML     78K 
36: R27         Commitments and Contingencies (Tables)              HTML     60K 
37: R28         Stock-Based Compensation (Tables)                   HTML    161K 
38: R29         Net Loss Per Share (Tables)                         HTML     47K 
39: R30         Organization and Description of Business -          HTML     51K 
                Additional Information (Details)                                 
40: R31         Summary of Significant Accounting Policies -        HTML     67K 
                Additional Information (Details)                                 
41: R32         Summary of Significant Accounting Policies -        HTML     46K 
                Schedule of Accounts Receivable Balances and                     
                Revenues as Percentage of Total Accounts                         
                Receivable Balances and Revenues (Details)                       
42: R33         Variable Interest Entities - Additional             HTML     29K 
                Information (Details)                                            
43: R34         Strategic Transformation - Additional Information   HTML     39K 
                (Details)                                                        
44: R35         Strategic Transformation - Summary of Results of    HTML     54K 
                Discontinued Operations (Details)                                
45: R36         Strategic Transformation - Summary of Carrying      HTML     33K 
                Amounts of the Classes of Assets and Liabilities                 
                of Discontinued Operations (Details)                             
46: R37         Revenues - Additional Information (Details)         HTML     24K 
47: R38         Revenues - Summary of Disaggregation of Revenues    HTML     40K 
                by Payor (Details)                                               
48: R39         Revenues - Summary Of Disaggregation Of Revenue     HTML     36K 
                classification (Details)                                         
49: R40         Balance Sheet Components - Summary of Prepaid       HTML     30K 
                Expenses and Other Current Assets (Details)                      
50: R41         Balance Sheet Components - Summary of Property and  HTML     44K 
                Equipment, Net (Details)                                         
51: R42         Balance Sheet Components - Schedule of Other        HTML     33K 
                Assets (Details)                                                 
52: R43         Balance Sheet Components - Additional Information   HTML     27K 
                (Details)                                                        
53: R44         Balance Sheet Components - Summary of Accrued       HTML     45K 
                Expenses and Other Current Liabilities (Details)                 
54: R45         Balance Sheet Components - Summary of Other         HTML     32K 
                Long-term Liabilities (Details)                                  
55: R46         Fair Value Measurements - Additional Information    HTML     33K 
                (Details)                                                        
56: R47         Fair Value Measurements - Summary of Inputs and     HTML     34K 
                Assumptions used to Determine Fair Value of                      
                Warrant Liability (Details)                                      
57: R48         Fair Value Measurements - Summary of Financial      HTML     40K 
                Assets and Liabilities Measured at Fair Value on                 
                Recurring Basis (Details)                                        
58: R49         Convertible Notes - Additional Information          HTML     90K 
                (Details)                                                        
59: R50         Related Party Transactions - Additional             HTML     39K 
                Information (Details)                                            
60: R51         Commitments and Contingencies - Additional          HTML     96K 
                Information (Details)                                            
61: R52         Commitments and Contingencies - Schedule of Net     HTML     41K 
                Minimum Payments Under Non-Cancelable Operating                  
                Leases (Details)                                                 
62: R53         Stockholders' Equity - Additional Information       HTML    136K 
                (Details)                                                        
63: R54         Stock-Based Compensation - Additional Information   HTML     54K 
                (Details)                                                        
64: R55         Stock-Based Compensation - Summary of Stock         HTML     72K 
                Options Activity under Plans (Details)                           
65: R56         Stock-Based Compensation - Summary of Assumptions   HTML     40K 
                used to Determine Fair Value of Stock Options                    
                Granted (Details)                                                
66: R57         Stock-Based Compensation - Summary of Restricted    HTML     44K 
                Stock Units Activity (Details)                                   
67: R58         Stock-Based Compensation - Schedule of Stock-based  HTML     33K 
                Compensation Expense (Details)                                   
68: R59         Income Taxes - Additional Information (Details)     HTML     34K 
69: R60         Net Loss Per Share - Summary of Potentially         HTML     35K 
                Dilutive Securities Not Included in Calculation of               
                Diluted Loss Per Share (Details)                                 
72: XML         IDEA XML File -- Filing Summary                      XML    139K 
70: XML         XBRL Instance -- bior-20220630_htm                   XML   2.38M 
71: EXCEL       IDEA Workbook of Financial Reports                  XLSX    155K 
 7: EX-101.CAL  XBRL Calculations -- bior-20220630_cal               XML    167K 
 6: EX-101.DEF  XBRL Definitions -- bior-20220630_def                XML    774K 
 5: EX-101.LAB  XBRL Labels -- bior-20220630_lab                     XML   1.46M 
 9: EX-101.PRE  XBRL Presentations -- bior-20220630_pre              XML   1.06M 
 8: EX-101.SCH  XBRL Schema -- bior-20220630                         XSD    185K 
73: JSON        XBRL Instance as JSON Data -- MetaLinks              444±   731K 
74: ZIP         XBRL Zipped Folder -- 0000950170-22-017429-xbrl      Zip    441K 




        
Filing Submission 0000950170-22-017429 – SGML Text

Original SGML Text submitted by:  Donnelley Financial Solutions/FA  (as Filing Agent) 

To view the SGML, please refresh
Refresh emoji
this page.


Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 7, 8:25:17.3am ET